Rapport's epilepsy drug clears mid-stage bipolar mania trial

Overview

Updated Yesterday

Rapport Therapeutics' epilepsy pill beat placebo in a mid-stage bipolar mania trial, results announced Oct. 20. Patients on RAP-219 improved 15.4 points on a 60-point mania scale over three weeks, versus 12.3 for placebo. The 3.1-point gap was statistically significant — but barely.

RAP-219 targets a regulatory protein tied to AMPA receptors that control glutamate signaling, a pathway overactive in both seizures and mania. Analysts at Stifel had low expectations; Jefferies called the safety profile "clean." If later trials hold, the drug would be the first new mechanism for acute mania in decades, with analysts seeing a billion-dollar-plus opportunity across seizures and bipolar.

Why it matters

A tolerable new mechanism for acute mania could displace older drugs patients abandon over side effects, unlocking a billion-dollar market.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

253

Patients randomized in Phase 2

Adults with bipolar I disorder in acute mania; 126 on RAP-219, 127 on placebo.

3.1 points

Placebo-adjusted YMRS improvement at week 3

Drug patients improved 15.4 points vs 12.3 for placebo on the Young Mania Rating Scale.

p = 0.045

Primary endpoint significance

The placebo-adjusted difference cleared the threshold, but analysts noted it was close to not hitting.

$436M

Cash position as of June 30, 2026

Expected to fund operations into the second half of 2029.

3.2% vs 0.8%

Discontinuation due to adverse events, drug vs placebo

Overall discontinuation was higher on drug (24.6% vs 11.8%), driven mostly by consent withdrawal.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Abraham Ceesay

Chief executive officer, Rapport Therapeutics

Leading RAP-219 development across seizures and bipolar mania

Andrew Tsai

Analyst, Jefferies

Called RAP-219's safety "clean" in an Oct. 20 client note

Paul Matteis

Analyst, Stifel

Had flagged low expectations before the trial readout

Organizations Involved

Rapport Therapeutics

Clinical-stage biotech

Developer of RAP-219; reporting Phase 2 success in bipolar mania

Boston-based biotech developing RAP-219, a drug that modulates TARPγ8-dependent AMPA receptor activity, for seizures and bipolar mania.

Johnson & Johnson

Pharmaceutical company

Licensor of RAP-219 to Rapport

J&J licensed RAP-219 to Rapport, which is developing the drug for seizures and bipolar mania.

U.S. Food and Drug Administration

Federal regulatory agency

End-of-Phase 2 meeting with Rapport planned for 1Q 2027

The FDA will review RAP-219's Phase 2 data and Phase 3 trial design early in 2027.

Timeline

1 event Latest: Yesterday

October 2026
RAP-219 meets primary endpoint in Phase 2 bipolar mania trial
Latest Clinical trial results

Rapport announced RAP-219 improved mania scores by 3.1 points over placebo at week 3 (p=0.045) in a 253-patient study, hitting both primary and key secondary endpoints.
Yesterday

Scenarios

Rapport launches Phase 3 program in bipolar mania on schedule

Likely Resolves by End of 2027

Discussed by: Rapport's own guidance; Guggenheim raised probability of success to 65% from 45%

Rapport plans an end-of-Phase 2 meeting with the FDA in the first quarter of 2027, then start two late-stage trials in acute bipolar mania in the second half of the year. The Phase 3 program will test a higher 1.25 mg dose and add sites outside the US, where neuropsychiatric trials have shown strong signal.

Phase 3 data confirm efficacy and RAP-219 heads toward approval

Possible Resolves by End of 2030

Discussed by: Jefferies; Guggenheim models peak bipolar sales of roughly $800 million

Jefferies called RAP-219's safety "clean" and noted efficacy in line with approved drugs. If the higher dose in Phase 3 improves efficacy without adding side effects, an approval filing would follow. Guggenheim models a 2030 launch for the mania indication, on top of roughly $2.3 billion in peak focal-onset seizure sales.

Phase 3 fails to replicate the Phase 2 result

Possible Resolves by End of 2030

Discussed by: Stifel's Paul Matteis flagged the borderline p-value and low-end efficacy

The Phase 2 win was narrow — p=0.045 — and efficacy sat at the low end of the range competitive with approved drugs. Overall discontinuation during treatment was higher on drug (24.6% vs 11.8%), mostly from consent withdrawal. Psychiatric trials carry a high late-stage failure rate, which is why expectations entering the study were low.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1990s–2000s

Antiepileptics become mood stabilizers

Valproate and lamotrigine, both developed as epilepsy drugs, were repurposed as treatments for bipolar disorder. They joined lithium as standard maintenance and acute therapies for the illness.

Then

Gave psychiatrists new options for patients who did not respond to lithium or antipsychotics.

Now

Established the crossover from seizure to mood indications — the same path RAP-219 is taking.

Why this matters now

RAP-219 follows a proven precedent of epilepsy drugs treating bipolar disorder, but with a mechanism-targeted approach rather than broad receptor effects. The Phase 2 win extends that crossover to a molecule designed for a specific pathway.

1949–present